Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

17.26 -0.08 (-0.46%)
Streaming Delayed Price Updated: 12:33 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 254,984
Open 17.30
Bid (Size) 17.26 (2)
Ask (Size) 17.29 (3)
Prev. Close 17.34
Today's Range 17.01 - 17.53
52wk Range 9.600 - 19.09
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily

Performance

YTD
-1.4%
-1.4%
1 Month
+7.5%
+7.5%
3 Month
+30.8%
+30.8%
6 Month
+6.2%
+6.2%
1 Year
+40.2%
+40.2%

More News

Read More
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday
Via Benzinga
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
AeroVironment Posts Downbeat Results, Joins Box, CrowdStrike And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Wake Up to This Biotech Stock That Still Has Big Potential Upside
Via MarketBeat
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers
Via Benzinga
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
Via Investor's Business Daily
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire

Frequently Asked Questions

Is Centessa Pharmaceuticals plc - American Depositary Shares publicly traded?
Yes, Centessa Pharmaceuticals plc - American Depositary Shares is publicly traded.
What exchange does Centessa Pharmaceuticals plc - American Depositary Shares trade on?
Centessa Pharmaceuticals plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Centessa Pharmaceuticals plc - American Depositary Shares?
The ticker symbol for Centessa Pharmaceuticals plc - American Depositary Shares is CNTA on the Nasdaq Stock Market
What is the current price of Centessa Pharmaceuticals plc - American Depositary Shares?
The current price of Centessa Pharmaceuticals plc - American Depositary Shares is 17.26
When was Centessa Pharmaceuticals plc - American Depositary Shares last traded?
The last trade of Centessa Pharmaceuticals plc - American Depositary Shares was at 08/20/25 12:33 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.